Last reviewed · How we verify
Sibutramine-Metformin
Sibutramine-Metformin is a combination drug that suppresses appetite through norepinephrine reuptake inhibition while improving insulin sensitivity and glucose metabolism.
Sibutramine-Metformin is a combination drug that suppresses appetite through norepinephrine reuptake inhibition while improving insulin sensitivity and glucose metabolism. Used for Obesity with or without type 2 diabetes mellitus, Weight management in patients with metabolic syndrome.
At a glance
| Generic name | Sibutramine-Metformin |
|---|---|
| Also known as | combination therapy |
| Sponsor | Laboratorios Silanes S.A. de C.V. |
| Drug class | Combination antiobesity and antidiabetic agent |
| Target | Norepinephrine transporter (NET), serotonin transporter (SERT); AMP-activated protein kinase (AMPK) |
| Modality | Small molecule |
| Therapeutic area | Endocrinology / Obesity / Diabetes |
| Phase | Phase 3 |
Mechanism of action
Sibutramine acts as a norepinephrine and serotonin reuptake inhibitor, increasing satiety and reducing food intake. Metformin decreases hepatic glucose production and improves peripheral insulin sensitivity. Together, they target weight loss and glycemic control through complementary mechanisms in obesity and type 2 diabetes management.
Approved indications
- Obesity with or without type 2 diabetes mellitus
- Weight management in patients with metabolic syndrome
Common side effects
- Dry mouth
- Insomnia
- Headache
- Gastrointestinal disturbance (metformin component)
- Tachycardia
- Hypertension
Key clinical trials
- Efficacy and Safety of Sibutramin-containing Drugs in Patient With Alimentary Obesity (PHASE4)
- Sibutramine-metformin Combination Versus Sibutramine and Metformin Monotherapy in Obese Patients (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Sibutramine-Metformin CI brief — competitive landscape report
- Sibutramine-Metformin updates RSS · CI watch RSS
- Laboratorios Silanes S.A. de C.V. portfolio CI